Crispr Therapeutics Ag (CRSP)
$55.34 0.00 (0.00%)
18:10 EST CRSP Stock Quote Delayed 15 Minutes
Previous Close $55.34
Market Cap 2.59B
PE Ratio -
Volume (Avg. Vol.)
Day's Range 55.34 - 55.34
52-Week Range 29.34 - 74.00
Dividend & Yield N/A (N/A)
CRSP Stock Predictions, Articles, and Crispr Therapeutics Ag News
- From InvestorPlace
- From the Web
Biotech stocks pulled off an impressive rally to finish 2019 strong. These names in the industry are looking to do the same in 2020.
It's no secret Matt McCall is searching for emerging trends. This week, he discusses cannabis stocks and a breakthrough biotech therapy.
CRISPR is a great addition to your stock wish list. If we get a correction, this is a solid long-term addition to your portfolio.
Uncertainty is a constant risks for biotech stocks. Which ones matter? Some are down so much investors cannot ignore them now.
Biotech stocks targeting gene therapy are going to be huge. Here are 3 gene therapy stocks to buy that have a ton of potential.
Government is scrutinizing the drug development and approval process and creating uncertainties among biotech stocks. Time to buy?
InVitae, Crispr and Myriad are just some of the genomic testing stocks worth a look as DNA becomes a more important part of healthcare.
CRSP is testing its gene editing therapies in sicke cell disease and cancer. These therapies could eventually boost CRSP stock.
No matter what risks you think lay ahead for the market (trade war, rate hikes, government shutdown), none of them hurt gene therapy stocks
The future of genetic medicine is bright, but bumpy. But these bumps will provide many opportunities to buy DNA stocks along the way.
Gene-editing technology is going to be a game-changer in the future, which means the time to invest in CRISPR stocks is now.
The biotechnology and pharmaceutical sectors continue to offer great value for investors, and these five Big Pharma stocks stand out from the crowd.
Although Crispr’s gene splicing techniques are revolutionary, the rally in CRSP stock is coming to an end as investors question its valuation.
Though the biotech industry is down this year, there are still a few stocks which can strengthen your portfolio. Compare Brokers....
Investors in CRISPR Therapeutics AG (CRSP) saw new options begin trading today, for the March 6th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CRSP options chain for the new March 6th contracts and identified one put and one call contract of particular interest.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..
Investors in CRISPR Therapeutics AG (CRSP) saw new options become available this week, for the March 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CRSP options chain for the new March 20th contracts and identified one put and one call contract of particular interest.
Navellier RatingsPowered by Portfolio Grader